A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs) vs ART Plus Placebo in Treated Primary or Early Stage HIV Infection on Viral Control Off ART
Latest Information Update: 22 Apr 2024
At a glance
- Drugs Teropavimab (Primary) ; Zinlirvimab (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms The RIO Trial
Most Recent Events
- 16 Apr 2024 Planned End Date changed from 31 Mar 2025 to 31 Jul 2027.
- 16 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Jul 2027.
- 15 Jun 2023 Planned primary completion date changed from 30 Jun 2022 to 31 Dec 2023.